Malecare , via Malecare’s Advanced Disease Program Director Joel Nowak , is the first to break the following news:
Hot off the press- The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis SA’s new
chemotherapy drug for advanced prostate cancer.
The drug, Jevtana (cabazitaxe) extended by nearly 2-1/2 months the lives of men with prostate
cancer tumors that resist standard treatment with hormones as well as chemotherapy.
The drug will be used after taxotere has failed.
Another break for men with advanced prostate cancer.